gastrointestinal stromal tumors/cefalàlgia

L'enllaç es desa al porta-retalls

ArticlesAssaigs clínicsPatents

Trieu el tipus d'ordenació

14 resultats

Malignant Prolactinoma With Liver Metastases Masquerading as Metastatic Gastrointestinal Stromal Tumor: A Case Report and Literature Review

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

Pituitary carcinomas are rare diseases defined as pituitary tumors with metastases. In this report, we describe a case of malignant prolactinoma with liver metastases masquerading as metastatic gastrointestinal stromal tumor (GIST). A 54-years-old woman received dopamine agonists for

Gastrointestinal stromal tumor with intracranial metastasis: case presentation and systematic review of literature.

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

Intracranial metastasis of Gastrointestinal Stromal Tumors (GISTs) is rare but presents unique treatment challenges. We present a case of intracranial metastasis of GIST with a systematic review of the literature. A literature search using key terms "'gastrointestinal stromal

A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

OBJECTIVE Heat shock protein 90 (HSP90) is required for the proper folding, function, and stability of various client proteins, two of which (KIT and PDGFRα) are critical in the pathogenesis and progression of gastrointestinal stromal tumors (GIST). This phase I study investigated the safety and

A rare serious case of retroperitoneal paraganglioma misdiagnosed as duodenal gastrointestinal stromal tumor: a case report.

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

Pheochromocytoma (PCC) and Paraganglioma (PGL) are rare neuroendocrine neoplasms. These tumors harbour disastrous consequences during surgery due to catecholamine hypersecretion if they are undiagnosed or prepared inadequately preoperatively.A 41- year- old

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST).

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

Imatinib (Gleevec) is a biological agent that is approved for the treatment of chronic myeloid leukemia (CML) as well as gastrointestinal stromal tumor (GIST). The most frequently seen adverse effects in patients treated with imatinib include superficial edema, muscle cramps, musculoskeletal pain,

Cerebellar metastasis of gastrointestinal stromal tumor: A case report and review of the literature.

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

BACKGROUND Intracranial metastases of gastro intestinal tumors are very rare. To the best of our knowledge only few cases were reported on the literature. METHODS We describe the case of 66-year-old male that presented with headache and vomiting. Physical examination found a kinetic cerebellar

Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis.

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

Tyrosine kinase receptors play an important role in tumor angiogenesis and, their implication in epithelial thyroid tumor growth has been highlighted. Sunitinib is a novel tyrosine kinase inhibitor, approved in 2006 by Food and Drug Administration for the treatment of advanced renal cell and

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML).

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

Imatinib (Gleevec; STI-571) is a tyrosine-kinase inhibitor (TKI) used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) as well as gastrointestinal stromal tumor (GIST). The most common adverse effects with imatinib include

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

BACKGROUND Imatinib is a tyrosine kinase inhibitor that has been established as a highly effective therapy for chronic myelogenous leukemia and gastrointestinal stromal tumors. A new generic, once-daily 400-mg tablet of imatinib has been developed by a pharmaceutical company in Argentina, where the

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

BACKGROUND Nilotinib, a second-generation tyrosine kinase inhibitor (TKI) formerly known as AMN107, was approved by the US Food and Drug Administration (FDA) on October 29, 2007, for the treatment of adult patients with chronic-phase (CP) and accelerated-phase (AP) Philadelphia chromosome-positive

Subdural hematoma in a patient taking imatinib for GIST: a case report and discussion of risk with other chemotherapeutics.

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

Although anticancer drugs have existed for over 50 years, targeted drugs have only recently been marketed, and their side effects may not be completely understood. The patient is a 56-year-old woman with a gastrointestinal stromal tumor who presented with headache, nausea, and vomiting lasting 2

A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

OBJECTIVE To determine the maximum tolerated dose (MTD) dose-limiting toxicity, and pharmacokinetic and pharmacodynamic profile of TKI258 (formerly CHIR-258). METHODS A phase I dose escalating trial in patients with advanced solid tumors was performed. Treatment was initially as single daily doses

15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5.

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

The paraganglioma (PGL) syndromes types 1-5 are autosomal dominant disorders characterized by familial predisposition to PGLs, phaeochromocytomas (PCs), renal cell cancers, gastrointestinal stromal tumours and, rarely, pituitary adenomas. Each syndrome is associated with mutation in a gene encoding

Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.

Només els usuaris registrats poden traduir articles

Inicieu sessió / registreu-vos

OBJECTIVE SU5416 (semaxanib) is a small molecule inhibitor of the vascular endothelial growth factor (VEGF) receptor-2 and KIT receptor tyrosine kinases. This Phase II study was conducted to investigate the safety and efficacy of SU5416 for patients with soft tissue sarcomas. METHODS Thirteen

Uneix-te a la nostra
pàgina de Facebook

Herbal & Natural Medicine

La base de dades d’herbes medicinals més completa avalada per la ciència

Funciona en 55 idiomes
Cures a base d'herbes recolzades per la ciència
Reconeixement d’herbes per imatge
Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
Llegiu publicacions científiques relacionades amb la vostra cerca
Cerqueu herbes medicinals pels seus efectes
Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents

Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades